8-K: Pyxis Oncology Appoints Interim CEO Amid Leadership Shift

Pyxis Oncology announces the departure of CEO Dr. Lara Sullivan and the appointment of current director Tom Civik as Interim CEO to ensure strategic continuity.

Summary

• Dr. Lara Sullivan ceased serving as Chief Executive Officer, principal executive officer, and Chief Medical Officer of Pyxis Oncology, Inc. effective February 2, 2026.
• Tom Civik, a current director of the company, was appointed Interim Chief Executive Officer and principal executive officer, effective February 2, 2026.
• Mr. Civik's interim term will continue until the termination of his employment agreement or the appointment of a permanent Chief Executive Officer.
• He will receive an annualized base salary of $710,000 and be eligible for a target bonus equal to 60% of his annualized base salary, prorated based on service and achievement of Board-established objectives.
• Mr. Civik will be granted an option to purchase shares representing 1.1% of the company's outstanding common stock, vesting in 12 equal monthly installments.
• He will also receive a 'Top-up Grant' option for 0.4% of outstanding common stock, fully vested upon the completion of a successful financing or strategic transaction.
• The Board of Directors has initiated a structured search for a permanent Chief Executive Officer.
• Pyxis Oncology's lead program, micvotabart pelidotin (MICVO), continues to advance in a Phase 1 monotherapy study and a Phase 1/2 combination study with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development given the appointment of a highly experienced interim CEO who is already familiar with the company, mitigating some of the uncertainty typically associated with CEO departures. The continuity of clinical programs is also a strong point.

Positives

• Appointment of Tom Civik, a highly experienced biotechnology executive and current director, as Interim CEO, ensuring leadership continuity and deep familiarity with the company's strategy and programs.
• Mr. Civik brings a proven track record, including leading Five Prime Therapeutics through its $1.9 billion acquisition by Amgen and driving significant growth at Foundation Medicine.
• The company's established clinical development leadership team will continue to execute ongoing trials and operational priorities without interruption.
• The lead program, MICVO, continues to advance in Phase 1 and Phase 1/2 clinical studies for difficult-to-treat cancers, including Fast Track Designation from the U.S. FDA for R/M HNSCC.

Negatives

• Departure of Dr. Lara Sullivan, M.D., who served as President, CEO, and Chief Medical Officer for six years, introduces a period of interim leadership.
• The company is now in a transition phase, which may introduce some uncertainty until a permanent CEO is appointed.

Risks

• Actual events and circumstances may differ materially from forward-looking statements due to various factors, including those identified in the company's Quarterly Report on Form 10-Q filed on November 3, 2025, and other SEC filings.
• New risk factors can emerge over time, and management cannot predict all of them or assess their full impact on the business, which may cause actual results to differ materially from forward-looking statements.

Future Outlook

The company remains focused on prioritizing the execution of its current clinical programs and upcoming milestones, particularly the advancement of its lead candidate, MICVO, in ongoing Phase 1 and Phase 1/2 studies. The Board has initiated a structured search for a permanent Chief Executive Officer.

Management Comments

• "The Board has appointed Tom as Interim CEO to ensure strong leadership and continuity. Tom brings decades of proven experience across oncology development, commercialization, and company building. As a long-term and current Director, he has a deep understanding of Pyxis Oncology’s science and strategy, and we are confident in his ability to guide the organization forward while the Board conducts a comprehensive search for permanent leadership." John Flavin, Chairman of the Board.
• "On behalf of the Board, I would like to thank Lara for her commitment and contributions to Pyxis Oncology throughout a formative period for the Company, including advancing MICVO into the clinic and guiding the Company through a critical period of growth." John Flavin, Chairman of the Board.
• "Serving as President, Chief Executive Officer, and Chief Medical Officer of Pyxis Oncology has been a privilege. I have had the honor to lead Pyxis Oncology over the last six years and am proud of the progress the team has made in advancing MICVO. I am confident in the leadership team’s track record of expertise advancing later stage oncology assets and their ability to lead MICVO through its next stage of clinical development." Lara S. Sullivan, M.D.
• "As we move forward, I am committed to ensuring that we put our collective efforts towards evaluating the potential of MICVO in a timely fashion. Pyxis Oncology has built a strong scientific and clinical foundation, and we remain confident in the potential of our lead program." Thomas Civik, Interim Chief Executive Officer.

Industry Context

StockSavvy.ai notes that leadership transitions are common in the clinical-stage biotechnology sector, particularly as companies navigate critical development phases. The appointment of an interim CEO with a strong track record in oncology development and successful M&A, like Tom Civik, can provide stability and strategic direction during such periods. This move signals a focus on program continuity and potentially preparing for future strategic transactions or financing, aligning with industry trends where experienced leadership is crucial for advancing complex therapeutic pipelines.

Comparison to Industry Standards

• Tom Civik's experience leading Five Prime Therapeutics to a $1.9 billion acquisition by Amgen demonstrates a track record comparable to successful biotech exits in the industry.
• His role in launching the first FDA-approved pan-cancer comprehensive genomic profiling test at Foundation Medicine highlights expertise in a key area of precision oncology, which is an evolving industry standard.
• MICVO's Fast Track Designation from the U.S. FDA for R/M HNSCC indicates regulatory recognition of its potential, a positive signal often seen in promising oncology assets that meet unmet medical needs.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased stability and strategic focus with an experienced interim CEO, but also inherent uncertainty during the search for a permanent leader. The incentive structure for the interim CEO is tied to successful financing/strategic transactions, aligning interests.
• Employees: Assurance of program continuity and operational priorities without interruption, potentially reducing internal disruption and maintaining morale.
• Customers/Patients: Continued advancement of the lead program, MICVO, suggests ongoing commitment to developing therapeutics for difficult-to-treat cancers, which is positive for patient communities.

Next Steps

• The Board of Directors will conduct a comprehensive search for a permanent Chief Executive Officer.
• The company will continue to execute ongoing clinical trials for MICVO, including the Phase 1 monotherapy study and the Phase 1/2 combination study.
• The Civik employment agreement will be filed as an exhibit to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Key Dates

Recommendation

The departure of a CEO introduces uncertainty, but the appointment of a highly experienced interim CEO who is already familiar with the company and its programs, coupled with the stated continuity of clinical trials, suggests a managed transition. Investors should hold to observe the progress of the CEO search and the continued advancement of the MICVO program before making further investment decisions.

Keywords

Pyxis Oncology, PYXS, CEO change, Interim CEO, Tom Civik, Lara Sullivan, Biotechnology, Oncology, Clinical-stage, MICVO, micvotabart pelidotin, Head and Neck Squamous Cell Carcinoma, HNSCC, Antibody-drug conjugate, ADC, Leadership transition, SEC filing, 8-K